# INDIVIOR

Summary updated: 2026-10-02T13:30:38.448827Z
Canonical: https://finbar.com/research/companies/indivior

## Overview

Indivior is a specialty pharmaceutical company focused on medicines for opioid use disorder (OUD). Its defining products include SUBLOCADE, a long-acting buprenorphine injection, and SUBOXONE Film, a buprenorphine/naloxone treatment. The company describes its mission as helping people achieve long-term recovery from OUD through accessible, science-driven care. [1](https://app.finbar.com/go?id=P69411453)[2](https://app.finbar.com/go?id=P120093593)[3](https://app.finbar.com/go?id=P49403113)[4](https://www.indivior.com/our-company/our-culture)

Indivior is headquartered in Richmond, Virginia, and its products are available primarily in the United States, as well as in Canada, Australia, France and Germany. For the year ended December 31, 2025, it reported net revenue of approximately $1.239 billion. Indivior was established as a standalone company in 2014 following its separation from Reckitt Benckiser. [5](https://app.finbar.com/go?id=P17333534)[6](https://app.finbar.com/go?id=P57319956)[7](https://app.finbar.com/go?id=P21497797)[8](https://app.finbar.com/go?id=P16311499)[9](https://app.finbar.com/go?id=P22695398)
[1](https://app.finbar.com/go?id=P69411453)[2](https://app.finbar.com/go?id=P120093593)[3](https://app.finbar.com/go?id=P49403113)[4](https://www.indivior.com/our-company/our-culture)[5](https://app.finbar.com/go?id=P17333534)[6](https://app.finbar.com/go?id=P57319956)[7](https://app.finbar.com/go?id=P21497797)[8](https://app.finbar.com/go?id=P16311499)[9](https://app.finbar.com/go?id=P22695398)[4](https://www.indivior.com/our-company/our-culture)

## Products & services

Indivior’s principal products are medicines for opioid use disorder (OUD). SUBLOCADE is a healthcare-practitioner-administered, long-acting buprenorphine injection for moderate-to-severe OUD, supplied in 100 mg and 300 mg doses for monthly treatment. The doses are designed to maintain therapeutic buprenorphine plasma levels; the product is distributed through a closed system. Updated initiation instructions permit treatment after a single transmucosal buprenorphine dose and observation, with a second injection possible one week later. [10](https://app.finbar.com/go?id=P92646561)[11](https://app.finbar.com/go?id=P103376298)[12](https://app.finbar.com/go?id=P73504160)[13](https://app.finbar.com/go?id=P29011872)[14](https://app.finbar.com/go?id=P98709630) SUBOXONE Film combines buprenorphine and naloxone in a fast-dissolving film for sublingual or buccal use, with strengths from 2 mg/0.5 mg to 12 mg/3 mg; it remains available, though Indivior stopped U.S. promotion and detailing in 2020. [15](https://app.finbar.com/go?id=P57043813)[16](https://app.finbar.com/go?id=P3832644)[17](https://app.finbar.com/go?id=P50046328) SUBUTEX is a sublingual buprenorphine tablet in 0.4 mg, 2 mg, and 8 mg strengths, distributed principally in Australia, France, and Germany. [18](https://app.finbar.com/go?id=P115396327)

Other products include SUBOXONE Tablet, a buprenorphine/naloxone medicine in a 4:1 ratio, available in 2 mg/0.5 mg and 8 mg/2 mg strengths and distributed on a transition basis in a limited number of countries. [19](https://app.finbar.com/go?id=P34911847) PERSERIS is an extended-release risperidone injection for schizophrenia, historically supplied as once-monthly 90 mg or 120 mg doses; Indivior announced the end of its availability in 2026. [20](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210655s010lbl.pdf)[21](https://www.indivior.com/our-products/discontinue-availability-of-perseris) OPVEE is nalmefene nasal spray for emergency treatment of known or suspected opioid overdose in adults and people aged 12 and older; Indivior discontinued sales and marketing support in 2025 but said it would continue distribution on request and meet applicable obligations. [22](https://app.finbar.com/go?id=P121343826)[7](https://app.finbar.com/go?id=P21497797)

In the first half of 2026, SUBLOCADE accounted for 74% of Indivior’s net revenue and other buprenorphine-based sublingual products accounted for 25%. [23](https://app.finbar.com/go?id=P145730767) Indivior’s filings describe its core products as prescription medicines and do not identify a separate services offering or services-revenue stream. [23](https://app.finbar.com/go?id=P145730767)
[10](https://app.finbar.com/go?id=P92646561)[11](https://app.finbar.com/go?id=P103376298)[12](https://app.finbar.com/go?id=P73504160)[13](https://app.finbar.com/go?id=P29011872)[14](https://app.finbar.com/go?id=P98709630)[15](https://app.finbar.com/go?id=P57043813)[16](https://app.finbar.com/go?id=P3832644)[17](https://app.finbar.com/go?id=P50046328)[18](https://app.finbar.com/go?id=P115396327)[19](https://app.finbar.com/go?id=P34911847)[22](https://app.finbar.com/go?id=P121343826)[7](https://app.finbar.com/go?id=P21497797)[23](https://app.finbar.com/go?id=P145730767)[20](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210655s010lbl.pdf)[21](https://www.indivior.com/our-products/discontinue-availability-of-perseris)[20](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210655s010lbl.pdf)[21](https://www.indivior.com/our-products/discontinue-availability-of-perseris)

## Geographic presence

The United States is Indivior’s largest market. The company reported that Australia, Canada, France and Germany together accounted for 76% of 2025 Rest of World net revenue. It also announced plans to cease operations and product sales in the U.K., Ireland, Sweden, Israel, Finland and Italy. [7](https://app.finbar.com/go?id=P21497797)[24](https://app.finbar.com/go?id=P76856615) FY2025 net revenue was $1,053 million in the U.S. (about 85%) and $186 million in Rest of World (about 15%), out of $1,239 million total; the company reports foreign revenue as a combined Rest of World figure rather than by individual country. [25](https://app.finbar.com/go?id=T2463876) In the six months ended June 30, 2026, U.S. revenue was $572 million (about 87%) and Rest of World revenue was $88 million (about 13%), out of $660 million total. [26](https://app.finbar.com/go?id=T16677552)

Indivior reported its headquarters in North Chesterfield, Virginia. Its FY2025 facility list included offices in Richmond, Virginia; Slough, England; and Fort Collins, Colorado; manufacturing and warehousing in Raleigh, North Carolina; and a fine-chemical manufacturing plant and R&D facility in Hull, England. [27](https://app.finbar.com/go?id=P50015082)[28](https://app.finbar.com/go?id=T3849021) At December 31, 2025, the company had 838 employees worldwide: 593 in the U.S. and 245 outside the U.S.; no further country-level employee breakdown was reported. [29](https://app.finbar.com/go?id=P69384148)
[7](https://app.finbar.com/go?id=P21497797)[24](https://app.finbar.com/go?id=P76856615)[25](https://app.finbar.com/go?id=T2463876)[25](https://app.finbar.com/go?id=T2463876)[25](https://app.finbar.com/go?id=T2463876)[26](https://app.finbar.com/go?id=T16677552)[26](https://app.finbar.com/go?id=T16677552)[26](https://app.finbar.com/go?id=T16677552)[27](https://app.finbar.com/go?id=P50015082)[28](https://app.finbar.com/go?id=T3849021)[29](https://app.finbar.com/go?id=P69384148)

## Business segments

Indivior reports one operating and reportable segment, comprising the company’s consolidated business. Its focus is developing, manufacturing and selling buprenorphine-based prescription medicines for opioid dependence and opioid use disorder; therefore, the single segment represents 100% of reported revenue. [30](https://app.finbar.com/go?id=P22616087) The latest interim filing, for the six months ended June 30, 2026, also describes the company as operating as one business segment. [23](https://app.finbar.com/go?id=P145730767)

For FY2025, Indivior reported net revenue of $1,239 million: $1,053 million from the U.S. (approximately 85%) and $186 million from the rest of the world (approximately 15%). These are geographic revenue contributions, not separate reportable segments. [25](https://app.finbar.com/go?id=T2463876)
[30](https://app.finbar.com/go?id=P22616087)[23](https://app.finbar.com/go?id=P145730767)[25](https://app.finbar.com/go?id=T2463876)[25](https://app.finbar.com/go?id=T2463876)[25](https://app.finbar.com/go?id=T2463876)

## Company history

Indivior traces its origins to 1994, when Reckitt Benckiser established a buprenorphine business group focused on treatments for opioid dependence. The U.S. FDA approved SUBOXONE sublingual tablets in 2002 and SUBOXONE film in 2010, milestones in the development of the company’s opioid-dependence treatment business. [31](https://www.indivior.com/our-company/indivior-history)

Indivior became an independent company in 2014 following its demerger from Reckitt Benckiser; it began trading on the London Stock Exchange in December. [32](https://ir.indivior.com/shareholder-information/investor-faqs)[33](https://prod.indivior.com/resources/dam/id/197/INDIVIOR_Annual_Report_2014.pdf) It expanded beyond sublingual treatments with FDA approval of the long-acting opioid-use-disorder treatment SUBLOCADE in 2017 and the schizophrenia treatment PERSERIS in 2018; both were launched in the United States in 2018 and 2019, respectively. [34](https://www.indivior.com/latest/category/news/2017/fda-approves-sublocade-the-first-and-only-once-monthly-injectable-buprenorphine-forumulation)[35](https://www.indivior.com/latest/category/press-releases/2018/sublocade-is-now-available-as-first-and-only-monthly-injectable-buprenorphine-in-the-us)[36](https://www.indivior.com/latest/category/news/2018/fda-approves-perseris-for-extended-release-injectable-suspension)[37](https://www.indivior.com/latest/category/news/2019/indivior-announces-launch-of-perseris-for-treatment-of-schizophrenia-in-adults)

In 2023, Indivior completed its acquisition of Opiant Pharmaceuticals, broadening its portfolio; Opiant-developed OPVEE, a nalmefene nasal spray, received FDA approval that year. [38](https://www.indivior.com/latest/category/press-releases/2023/indivior-completes-acquisition-of-opiant-pharmaceuticals-inc)[39](https://www.indivior.com/latest/category/news/2023/indiviorplc-opvee-approval)
[31](https://www.indivior.com/our-company/indivior-history)[32](https://ir.indivior.com/shareholder-information/investor-faqs)[33](https://prod.indivior.com/resources/dam/id/197/INDIVIOR_Annual_Report_2014.pdf)[34](https://www.indivior.com/latest/category/news/2017/fda-approves-sublocade-the-first-and-only-once-monthly-injectable-buprenorphine-forumulation)[35](https://www.indivior.com/latest/category/press-releases/2018/sublocade-is-now-available-as-first-and-only-monthly-injectable-buprenorphine-in-the-us)[36](https://www.indivior.com/latest/category/news/2018/fda-approves-perseris-for-extended-release-injectable-suspension)[37](https://www.indivior.com/latest/category/news/2019/indivior-announces-launch-of-perseris-for-treatment-of-schizophrenia-in-adults)[38](https://www.indivior.com/latest/category/press-releases/2023/indivior-completes-acquisition-of-opiant-pharmaceuticals-inc)[39](https://www.indivior.com/latest/category/news/2023/indiviorplc-opvee-approval)

## Sources

1. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P69411453)
2. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P120093593)
3. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P49403113)
4. [www.indivior.com](https://www.indivior.com/our-company/our-culture)
5. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P17333534)
6. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P57319956)
7. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P21497797)
8. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P16311499)
9. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P22695398)
10. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P92646561)
11. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P103376298)
12. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P73504160)
13. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P29011872)
14. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P98709630)
15. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P57043813)
16. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P3832644)
17. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P50046328)
18. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P115396327)
19. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P34911847)
20. [www.accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210655s010lbl.pdf)
21. [www.indivior.com](https://www.indivior.com/our-products/discontinue-availability-of-perseris)
22. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P121343826)
23. [INDIVIOR — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145730767)
24. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P76856615)
25. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=T2463876)
26. [INDIVIOR — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16677552)
27. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P50015082)
28. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=T3849021)
29. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P69384148)
30. [INDIVIOR — Full financial report (2025 Y)](https://app.finbar.com/go?id=P22616087)
31. [www.indivior.com](https://www.indivior.com/our-company/indivior-history)
32. [ir.indivior.com](https://ir.indivior.com/shareholder-information/investor-faqs)
33. [prod.indivior.com](https://prod.indivior.com/resources/dam/id/197/INDIVIOR_Annual_Report_2014.pdf)
34. [www.indivior.com](https://www.indivior.com/latest/category/news/2017/fda-approves-sublocade-the-first-and-only-once-monthly-injectable-buprenorphine-forumulation)
35. [www.indivior.com](https://www.indivior.com/latest/category/press-releases/2018/sublocade-is-now-available-as-first-and-only-monthly-injectable-buprenorphine-in-the-us)
36. [www.indivior.com](https://www.indivior.com/latest/category/news/2018/fda-approves-perseris-for-extended-release-injectable-suspension)
37. [www.indivior.com](https://www.indivior.com/latest/category/news/2019/indivior-announces-launch-of-perseris-for-treatment-of-schizophrenia-in-adults)
38. [www.indivior.com](https://www.indivior.com/latest/category/press-releases/2023/indivior-completes-acquisition-of-opiant-pharmaceuticals-inc)
39. [www.indivior.com](https://www.indivior.com/latest/category/news/2023/indiviorplc-opvee-approval)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.